PP  Vol.6 No.3 , March 2015
Antidiabetic Effects of Omega-3 Polyunsaturated Fatty Acids: From Mechanism to Therapeutic Possibilities
Abstract: Diabetes mellitus (DM) is chronic disease characterized by hyperglycemia and insulin resistance caused by dysfunction of pancreatic β cells. Over the past few decades, epidemiological studies have suggested that dietary long-chain polyunsaturated fatty acids such as docosahexaenoic acid and eicosapentaenoic acid decrease the risk of metabolic diseases including DM. The mechanisms underlying the therapeutic efficacy of dietary long-chain polyunsaturated fatty acids in treating DM have been partly revealed. In this review, the authors describe the antidiabetic effects of long-chain polyunsaturated fatty acids and also discuss their possibilities as therapeutics for DM in the light of recent findings.
Cite this paper: Iwase, Y. , Kamei, N. and Takeda-Morishita, M. (2015) Antidiabetic Effects of Omega-3 Polyunsaturated Fatty Acids: From Mechanism to Therapeutic Possibilities. Pharmacology & Pharmacy, 6, 190-200. doi: 10.4236/pp.2015.63020.

[1]   World Health Organization (2015) Diabetes. Fact Sheet No. 312.

[2]   American Diabetes Association (2012) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 35, S64-S71.

[3]   de la Monte, S.M. and Wands, J.R. (2008) Alzheimer’s Disease is Type 3 Diabetes-Evidenced Review. Journal of Diabetes Science and Technology, 2, 1101-11138.

[4]   Duarte, A.I., Candeias, E., Correia, S.C., et al. (2013) Crosstalk between Diabetes and Brain: Glucagon-Like Peptide-1 Mimetics as a Promising Therapy against Neurodegeneration. Biochimica et Biophysica Acta, 1832, 527-541.

[5]   Janson, J., Laedtk, T., Parisi J.E., et al. (2004) Increases Risk of Type 2 Diabetes in Alzheimer’s Disease. Diabetes, 53, 474-481.

[6]   Takalo, M., Haapasalo, A., Martiskainen, H., et al. (2014) High-Fat Diet Increases Tau Expression in the Brain of T2DM and AD Mice Independently of Peripheral Metabolic Status. Journal of nutritional Biochemistry, 25, 634-641.

[7]   Freund, L.Y., Vedin, I., Cederholm, T., et al. (2014) Transfer of Omega-3 Fatty Acids across the Blood-Brain Barrier after Dietary Supplementation with a Docosahexaenoic Acid-Rich Omega-3 Fatty Acid Preparation in Patients with Alzheimer’s Disease: The OmegAD Study. Journal of International Medicine, 275, 428-436.

[8]   Weir, G.C., Laybutt, D.R., Kaneto, H., et al. (2001) Beta-Cell Adaptation and Decompensation during the Progression of Diabetes. Diabetes, 50, S154-S159.

[9]   Kanda, H., Tateya, S., Tamori, Y., et al. (2006) MCP-1 Contributes to Macrophage Infiltration into Adipose Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity. Journal of Clinical Investigation, 116, 1494-1505.

[10]   Kamei, N., Tobe, K., Suzuki, R., et al. (2006) Overexpression of Macrophage Chemoattractant Protein-1 in Adipose Tissue Cause Macrophage Recruitment and Insulin Resistance. The Journal of Biological Chemistry, 281, 26602-26614.

[11]   Flachs, P., Horakova, O., Brauner P., et al. (2005) Polyunsaturated Fatty Acids of Marine Origin up Regulate Mitochondrial Biogenesis and Induce β-Oxidation in White Fat. Diabetologia, 48, 2365-2375.

[12]   Vaughan, R.A., Garcia-Smith, R., Bisoffiet M., et al. (2012) Conjugated Linoleic Acid or Omega 3 Fatty Acids Increase Mitochondrial Biosynthesis and Metabolism in Skeletal Muscle Cells. Lipid in Health and Disease, 11, 142-152.

[13]   Weisberg, S.P., McCann, D., Desai, M., et al. (2003) Obesity Is Associated with Macrophage Accumulation in Adipose Tissue. Journal of Clinical Investigation, 112, 1796-1808.

[14]   Xu, H., Barnes, G.T., Yang, Q., et al. (2003) Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. Journal of Clinical Investigation, 112, 1821-1830.

[15]   Lazar, M.A. (2006) The Humoral Side of Insulin Resistance. Nature Medicine, 12, 43-44.

[16]   Sell, H. and Eckel, J. (2007) Monocyte Chemotactic Protein-1 and Its Role in Insulin Resistance. Current Opinion in Lipidology, 18, 258-262.

[17]   Sell, H. and Eckel, J. (2009) Chemotactic Cytokines, Obesity and Type 2 Diabetes: In Vivo and in Vitro Evidence for a Possible Causal Correlation? Proceedings of the Nutrition Society, 68, 378-384.

[18]   Pimentel, G.D., Lira, F.S., Rosa, J.C., et al. (2013) High-Fat Fish Oil Diet Prevents Hypothalamic Inflammatory Profile in Rats. ISRN Inflammation, 2013, Article ID: 419823.

[19]   Vandal, M., Alata, W., Tremblay, C., et al. (2014) Reduction in DHA Transport to the Brain of Mice Expressing Human APOE4 Compared to APOE2. Journal of Neurochemistry, 129, 516-526.

[20]   Afshordel, S., Hagl, S., Werner, D., et al. (2015) Omega-3 Polyunsaturated Fatty Acids Improve Mitochondrial Dysfunction in Brain Aging—Impact of Bcl-2 and NPD-1 Like Metabolites. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 92, 23-31.

[21]   Eckert, G.P., Chang, S., Eckmann, J., et al. (2011) Liposome-Incorporated DHA Increases Neuronal Survival by Enhancing Non-Amyloidogenic APP Processing. Biochimica et Biophysica Acta, 1808, 234-243.

[22]   Wellhauser, L. and Belsham, D.D. (2014) Activation of the Omega-3 Fatty Acid Receptor GPR120 Mediates Anti-Inflammatory Actions in Immortalized Hypothalamic Neurons. Journal of Neuroinflammation, 27, 60.

[23]   Cintra, D.E., Ropelle, E.R., Moraes, J.C., et al. (2012) Unsaturated Fatty Acids Revert Diet-Induced Hypothalamic Inflammation in Obesity. PLoS ONE, 7, e30571.

[24]   Zhao, Y., Calon, F., Julien, C., et al. (2011) Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARγ-Mediated Mechanisms in Alzheimer’s Disease Models. PLoS ONE, 6, e15816.

[25]   Wall, R., Ross, R.P., Fitzgerald, G.F. and Stanton, C. (2010) Fatty Acids from Fish: The Anti-Inflammatory Potential of Long-Chain Omega-3 Fatty Acids. Nutrition Reviews, 68, 280-289.

[26]   Bang, H.O. and Dyerberg, J. (1972) Plasma Lipids and Lipoproteins in Greenlandic West Coast Eskimos. Acta Medica Scandinavica, 192, 85-94.

[27]   Kromann, N. and Green, A. (1980) Epidemiological Studies in the Upernavik District, Greenland. Incidence of Some Chronic Diseases 1950-1974. Acta Medica Scandinavica, 208, 401-406.

[28]   Lim, G.E. and Brubaker, P.L. (2006) Glucagon-Like Peptide 1 Secretion by the L-Cell. The View from Within. Diabetes, 55, S70-S77.

[29]   Kieffer, T.J., McIntosh, C.H. and Pederson, R.A. (1995) Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV. Endocrinology, 136, 3585-3596.

[30]   Holst, J.J. (2006) Glucagon-Like Peptide-1: From Extract to Agent: The Claude Bernard Lecture, 2005. Diabetologia, 49, 253-260.

[31]   Drucker, D.J., Jin, T., Asa, S.L., et al. (2006) Activation of Proglucagon Gene Transcription by Protein Kinase-A in a Novel Mouse Enteroendocrine Cell Line. Molecular Endocrinology, 8, 1646-1655.

[32]   Abello, J., Ye, F., Bosshard, A., et al. (1994) Stimulation of Glucagon-Like Peptide-1 Secretion by Muscarinic Agonist in a Murine Intestinal Endocrine Cell Line. Endocrinology, 134, 2011-2017.

[33]   Reimer, R.A., Darimont, C., Gremlich, S., et al. (2001) A Human Cellular Model for Studying the Regulation of Glucagon-Like Peptide-1 Secretion. Endocrinology, 142, 4522-4528.

[34]   Drucker, D.J. (2006) The Biology of Incretin Hormones. Cell Metabolism, 3, 153-165.

[35]   Rocca, A.S. and Brubaker, P.L. (1999) Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion. Endocrinology, 140, 1687-1694.

[36]   Roberge, J.N. and Brubaker, P.L. (1993) Regulation of Intestinal Proglucagon-Derived Peptide Secretion by Glucose-Dependent Insulinotropic Peptide in a Novel Enteroendocrine Loop. Endcrinology, 133, 233-240.

[37]   Elrick, H., Stimmler, L., Hlad Jr., C.J. and Rai, Y. (1964) Plasma Insulin Responses to Oral and Intravenous Glucose Administration. Journal of Clinical Endocrinology Metabolism, 24, 1076-1082.

[38]   Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S., et al. (2001) Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. Journal of Clinical Endocrinology Metabolism, 86, 3717-3723.

[39]   Vilsbøll, T., Krarup, T., Deacon, C.F., et al. (2001) Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes, 50, 609-613.

[40]   Muscelli, E., Mari, A., Casolaro, A., et al. (2008) Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. Diabetes, 57, 1340-1348.

[41]   Vilsbøll, T., Agersø, H., Krarup, T. and Holst, J.J. (2003) Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 88, 220-224.

[42]   Green, C.J., Henriksen, T.I., Pedersen, B.K. and Solomon, T.P. (2012) Glucagon Like Peptide-1-Induced Glucose Metabolism in Differentiated Human Muscle Satellite Cells Is Attenuated by Hyperglycemia. PLoS ONE, 7, e44284.

[43]   Sonoki, K., Iwase, M. Takata, Y., et al. (2013) Effect of Thirty-Times Chewing per Bite on Secretion of Glucagon-Like Peptide-11 in Health Volunteers and Type 2 Diabetic Patients. Endocrine Journal, 60, 311-319.

[44]   Tsuchiya, M., Niijima-Yaoita, F., Yoneda, H., et al. (2014) Long-Term Feeding on Powdered Food Causes Hyperglycemia and Signs of Systemic Illness in Mice. Life Science, 103, 8-14.

[45]   Yamazaki, T., Yamori, M., Asai, K., et al. (2013) Mastication and Risk for Diabetes in Japanese Population: A Cross-Sectional Study. PLoS ONE, 8, e4113.

[46]   Rocca, A.S. and Brubaker, P.L. (1995) Stereospecific Effects of Fatty Acids on Proglucagon-Derived Peptide Secretion in Fetal Rat Intestinal Cultures. Endocrinology, 136, 5593-5599.

[47]   Brubaker, P.L., Schloos, J. and Drucker, D.J. (1998) Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line. Endocrinology, 139, 4108-4114.

[48]   Oh, D.Y., Talukdar, S., Bae, E.J., et al. (2010) GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin-Sensitizing Effects. Cell, 142, 687-698.

[49]   Hirasawa, A., Tsumaya, K., Awaji, T., et al. (2005) Free Fatty Acids Regulate Gut Incretin Glucagon-Like Peptide-1 Secretion through GPR120. Nature Medicine, 11, 90-94.

[50]   Katsuma, S., Hatae, N., Yano, T., et al. (2005) Free Fatty Acids Inhibit Serum Deprivation-Induced Apoptosis through GPR120 in a Murine Enteroendocrine Cell Line STC-1. Journal of Biological Chemistry, 280, 19507-19515.

[51]   Adachi, T., Tanaka, T., Takemoto, K., et al. (2006) Free Fatty Acids Administrated into the Colon Promote the Secretion of Glucagon-Like Peptide-1 and Insulin. Biochemical and Biophysical Research Communications, 340, 332-357.

[52]   Morishita, M., Tanaka, T., Shida, T. and Takayama, K. (2008) Usefulness of Colon Targeted DHA and EPA as Novel Diabetes Medications That Promote Intrinsic GLP-1 Secretion. Journal of Controlled Release, 132, 99-104.

[53]   Shida, T., Kamei, N. and Takeda-Morishita, M. (2013) Colonic Delivery of Docosahexaenoic Acid Improves Impaired Glucose Tolerance via GLP-1 Secretion and Suppresses Pancreatic Islet Hyperplasia in Diabetic KK-Ay Mice. International Journal of Pharmacology, 450, 63-69.

[54]   Morishita, M., Kajita, M., Suzuki, A., et al. (2000) The Dose-Related Hypoglycemic Effects of Insulin Emulsions Incorporating Highly Purified EPA and DHA. International Journal of Pharmacology, 201, 175-185.

[55]   Suzuki, A., Morishita, M., Kajita, M., et al. (1998) Enhanced Colonic and Rectal Absorption of Insulin Using a Multiple Emulsion Containing Eicosapentaenoic Acid and Docosahexaenoic Acid. Journal of Pharmaceutical Sciences, 87, 1196-1202.

[56]   Andersen, G., Harnack, K., Erbersdobler, H.F. and Somoza, V. (2008) Dietary Eicosapentaenoic Acid and Docosahexaenoic Acid Are More Effective than Alpha-Linolenic Acid in Improving Insulin Sensitivity in Rats. Annals of Nutrition and Metabolism, 52, 250-256.

[57]   Ichimura, A., Hirasawa, A., Poulain-Godefroy, O., et al. (2012) Dysfunction of Lipid Sensor GPR120 Leads to Obesity in Both Mouse and Human. Nature, 483, 350-354.

[58]   Oh, D.Y., Walenta, E., Akiyama, T.E., et al. (2014) A GPR120-Selective Agonist Improves Insulin Resistance and Chronic Inflammation in Obese Mice. Nature Medicine, 20, 942-947.

[59]   Luan, B., Zhao, J., Wu, H., et al. (2009) Deficiency of A Beta-Arrestin-2 Signal Complex Contributes to Insulin Resistance. Nature, 457, 1146-1149.

[60]   Spencer, M., Finlin, B.S., Unal, R., et al. (2013) Omega-3 Fatty Acids Reduce Adipose Tissue Macrophages in Human Subjects with Insulin Resistance. Diabetes, 62, 1709-17171.

[61]   de Caterina, R., Madonna, R., Bertolotto, A. and Schmidt, E.B. (2007) N-3 Fatty Acids in the Treatment of Diabetic Patients. Diabetes Care, 30, 1012-1026.

[62]   Labonté, M.è., Couture, P., Tremblay, A.J., Hogue, J.C., Lemelin, V. and Lamarche, B. (2013) Eicosapentaenoic and Docosahexaenoic Acid Supplementation and Inflammatory Gene Expression in the Duodenum of Obese Patients with Type 2 Diabetes. Nutrition Journal, 12, 98.

[63]   Brookheart, R.T., Michel, C.T. and Schaffer, J.F. (2009) As a Matter of Fat. Cell Metabolism, 10, 9-12.

[64]   Xu, J., Teran-Garcia, M., Park, J.H., et al. (2001) Polyunsaturated Fatty Acids Suppress Hepatic Sterol Regulatory Element-Binding Protein-1 Expression by Accelerating Transcript Decay. Journal of Biological Chemistry, 276, 9800-9807.

[65]   Xu, J., Nakamura, M.T., Cho, H.P. and Clarke, S.D. (2007) Sterol Regulatory Element Binding Protein-1 Expression Is Suppressed by Dietary Polyunsaturated Fatty Acids. Journal of Biological Chemistry, 274, 23577-23583.

[66]   Liu, X., Xue, Y., Liu, C., et al. (2013) Eiocasapentaenoic Acid-Enriched Phospholipid Ameliorates Insulin Resistance and Lipid Metabolism in Diet-Induced-Obese Mice. Lipid in Health and Disease, 12, 109.

[67]   Neschen, S., Morino, K., Dong, J., et al. (2007) N-3 Fatty Acids Preserve Insulin Sensitivity in Vivo in a Peroxisome Proliferator-Activated Receptor-α-Dependent Manner. Diabetes, 56, 1034-1041.

[68]   Wu, J.H., Cahill, L.E. and Mozaffarian, D. (2013) Effects of Fish Oil on Circulating Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Endocrinology and Metabolism, 98, 2451-2459.

[69]   Flachs, P., Mohamed-Ali, V. and Horakova, O. (2006) Polyunsaturated Fatty Acids of Marine Origin Induce Adiponectin in Mice Fed a High-Fat Diet. Diabetologia, 49, 394-397.

[70]   Banga, A., Unal, R., Tripathi, P., et al. (2009) Adiponectin Translation Is Increased by the PPARgamma Agonist Pioglitazone and Omega-3 Fatty Acids. American Journal of Physiology, Endocrinology and Metabolism, 296, E480-E489.

[71]   Tishinsky, J.M., Ma, D.W. and Robinson, L.F. (2011) Eicosapentaenoic Acid and Rosiglitazone Increase Adiponectin in an Additive and PPARγ-Dependent Manner in Human Adipocytes. Obesity, 19, 262-268.

[72]   World Health Organization. Diabetes Programme [Article Online].

[73]   Sawada, N., Jiang, A., Takizawa, F., et al. (2014) Endothelial PGC-1α Mediates Vascular Dysfunction in Diabetes. Cell Metabolism, 19, 246-258.

[74]   Cao, L., Aran, P.R., Kim, J., et al. (2010) Modulating Notch Signaling to Enhance Neovascularization and Reperfusion in Diabetic Mice. Biomaterials, 31, 9048-9056.

[75]   Bryner, R.W., Woodworth-Hobbs, M.E., Williamson, D.L. and Always, S.E. (2012) Docosahexaenoic Acid Protects Muscle Cells from Palmitate-Induced Atrophy. ISRN Obesity, 2012, Article ID: 647348.

[76]   Virtanen, J.K., Mursu, J., Voutilainen, S., Uusitupa, M. and Tuomainen, T.P. (2014) Serum Omega-3 Polyunsaturated Fatty Acids and Risk of Incident Type 2 Diabetes in Men: The Kuopio Ischemic Heart Disease Risk Factor Study. Diabetes Care, 37, 1189-1196.

[77]   Iwasaki, M., Hoshian, F., Tsuji, T., et al. (2012) Predicting Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Association of Glycated Hemoglobin Reduction with Serum Eicosapentaenoic Acid and Docosahexaenoic Acid Levels. Journal of Diabetes Investigation, 3, 464-467.

[78]   Samimi, M., Jamilian, M., Asemi, Z. and Esmaillzadeh, A. (2014) Effects of Omega-3 Fatty Acid Supplementation on Insulin Metabolism and Lipid Profiles in Gestational Diabetes: Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Nutrition, in press.

[79]   Serhiyenko, V., Serhiyenko, A. and Segin, V. (2014) The Effect of Omega-3 Polyunsaturated Fatty Acids on N-Terminal Pro-Brain Natriuretic Peptide and Lipid Concentration in Patients with Type 2 Diabetes Mellitus and Cardiovascular Autonomic Neuropathy. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 21, 97-101.